Government Pharmaceutical Development to Address High Prices: Challenges Ahead

The author examines proposals for government drug development as a means of lowering prices, concluding that while some costs (e.g., marketing costs) could be reduced, most development costs would remain unchanged and inefficiencies could worsen with greater government involvement. He argues that government manufacturing is unlikely to substantially improve drug development or lower costs in the long term.